Drugs / ANS03
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06716138 | Mar 2025 → Dec 2027 expected | NTRK fusion positive cancer | Avistone Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANS03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06716138 ↗ |
| Action | Inhibit | “ANS03 is a rationally next generation TKI targeting both ROS1 and NTRK” NCT06716138 ↗ |
| Modality | Small molecule | “ANS03 is a rationally next generation TKI” NCT06716138 ↗ |
| Target | ROS1 | “targeting both ROS1 and NTRK” NCT06716138 ↗ |